Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [3] Core Insights - The commercialization of ADC (Antibody-Drug Conjugates) is accelerating, with 20 ADC drugs approved globally, and 6 of them have been in the "billion-dollar club" for two consecutive years [30][31] - The report highlights the increasing competition in the ADC sector, with approximately 60 ADC drugs currently in clinical phase 3 and application stages [30] - Domestic innovative pharmaceutical companies are adopting various strategies for ADC capacity layout, with companies like Rongchang Biopharma transitioning from outsourcing to in-house production, while others like Kelong Biotechnology are building their own production bases [31][32] Summary by Sections Market Review - The pharmaceutical index rose by 0.14% this week, outperforming the CSI 300 index by 1.47 percentage points, ranking 15th in industry performance [10] - Year-to-date, the pharmaceutical index has increased by 3.28%, also outperforming the CSI 300 index by 2.99 percentage points, ranking 23rd [10] Individual Stock Performance - In the A-share market, 255 out of 479 pharmaceutical stocks rose, with the top five performers being Guangshengtang (+29.83%), Haixiang Pharmaceutical (+18.64%), and Meidixi (+18.04%) [20] - In the Hong Kong market, 38 out of 116 pharmaceutical stocks rose, with the top performers including Yiteng Jiahe (+14%) and Kedi-B (+9.96%) [24] Industry News and Policies - The newly revised "Regulations on the Implementation of the Drug Administration Law" supports segmented contract manufacturing and commercial-scale drug sales, providing a foundation for ADC commercialization cooperation [32] - Notable industry developments include Novartis's application for Ianalumab in China and Johnson & Johnson's approval of Daratumumab injection for multiple myeloma treatment [27][28] Weekly Insights - The ADC commercialization battle has begun, with a significant increase in demand for ADC production capacity, leading to a supply-demand imbalance [30] - Major CXO companies are expanding ADC production capacity, with companies like WuXi AppTec acquiring East Yao Pharmaceutical to meet rising orders [31]

Core Viewpoint - The beauty industry is expected to maintain steady growth in 2026, driven by product innovation and the rise of domestic brands, with Douyin's beauty GMV projected to grow over 20% year-on-year in January 2026, reflecting a marginal improvement during the off-season due to brand efforts in daily sales and self-broadcasting, alongside the impact of the Spring Festival timing [1][2]. Group 1: Strong Product and Brand Momentum - Companies with strong product and brand momentum are expected to achieve high growth through new product launches and category expansions, such as Ruoyuchen, which is focusing on high-end household cleaning and health products [3]. - Beijiaojie is maintaining stable performance in oral care and is expected to benefit from the trend of AKK ingredients in its probiotic raw material business [3]. - Maogeping is positioned as a high-end brand with ongoing expansion in offline counters and online sales, anticipating rapid growth across multiple product lines [3]. - Linqingxuan is benefiting from the trend of oil-based skincare, with its flagship essence oil performing well and new products showing promise [3]. - Shangmei Co. is expanding its main brand Han Shu and sub-brands, with strong growth expected from key products [3]. Group 2: Leading Brands with Strong Asset Value - Beitanie has been actively adjusting its channel and inventory mechanisms since 2025, leading to product structure upgrades and profit recovery, with strong GMV growth in January 2026 [4]. - Proya is expected to have a clear new product strategy in 2026, launching several key products and expanding its sub-brands to drive steady growth [4]. Investment Recommendations - Companies with strong fundamentals and high growth potential recommended for increased holdings include Ruoyuchen, Beijiaojie, Maogeping, Linqingxuan, and Shangmei Co. [5]. - Companies showing signs of bottom improvement include Beitanie, Proya, Dengkang Oral, Shanghai Jahwa, and Runben Co. [5].

Group 1: Internet & Technology Sector Insights - The Hang Seng Technology sector has seen a valuation recovery since early 2025, with a PE-TTM of 20.05, below historical averages, indicating potential for value investment [3] - Southbound capital has accelerated inflow into Hong Kong stocks, with significant increases in holdings of major internet companies, suggesting a focus on profitability and technology business realization [4] - The internet industry is stabilizing in user traffic, with a shift towards high-quality growth driven by generative AI, which is expected to reshape valuations [5] Group 2: Lithium Battery Industry Strategy - The lithium battery industry is entering a new cycle with strong demand driven by policy support and technological advancements, particularly in energy storage and electric vehicles [7] - The supply-demand relationship is improving, leading to price recovery across the lithium battery supply chain, with significant potential for material price increases in 2026 [9] - New technologies, such as solid-state batteries and sodium-ion batteries, are expected to accelerate industrialization, enhancing the growth prospects of the lithium battery sector [10] Group 3: BYD Company Analysis - BYD's January 2026 sales reached 210,000 units, with a strong performance in overseas markets, indicating a robust growth engine for the company [15] - The company is launching new models aimed at high-end markets, which are expected to enhance market share and brand influence [18] - Revenue forecasts for BYD from 2025 to 2027 are projected at 854.9 billion, 995.9 billion, and 1,111.7 billion yuan, with corresponding net profits of 35.73 billion, 50.19 billion, and 62.65 billion yuan [18] Group 4: Leap Motor Company Insights - Leap Motor delivered 32,000 vehicles in January 2026, marking a 27.4% year-on-year increase, with plans to reach a sales target of 1 million units for the year [19] - The company is set to launch several new models, enhancing its product lineup and market presence [20] - Revenue projections for Leap Motor from 2025 to 2027 are estimated at 66.27 billion, 104.12 billion, and 135.41 billion yuan, with significant growth anticipated [20] Group 5: Geely Automobile Performance - Geely's January 2026 sales reached 270,000 units, a 1.3% year-on-year increase, with strong performance in both fuel and electric vehicle segments [23] - The company is expanding its global strategy with new model introductions in overseas markets, which are expected to drive future growth [25] - Revenue forecasts for Geely from 2025 to 2027 are projected at 331.2 billion, 421.8 billion, and 485.8 billion yuan, with a focus on electric and high-end vehicle segments [25] Group 6: Long Wall Motor Company Overview - Long Wall Motor's January 2026 sales were 90,000 units, with a target of 1.8 million units for the year, indicating a positive sales trajectory [27] - The company is investing in new channels and models, which may impact short-term profitability but is expected to enhance long-term growth [28] - Revenue projections for Long Wall from 2025 to 2027 are estimated at 222.8 billion, 275.5 billion, and 309.8 billion yuan, with a focus on international expansion [29] Group 7: SpaceX and Commercial Aerospace Developments - SpaceX's acquisition of xAI and the approval of a million-satellite application signify a strategic push towards space-based computing and energy solutions [31][32] - The integration of AI and satellite technology is expected to drive significant advancements in space energy demand, particularly solar energy [34] - The commercial aerospace sector is anticipated to grow rapidly, with a focus on solar energy solutions and satellite deployment [35]

Investment Rating - The report recommends a focus on the company, indicating that it is undervalued with a reasonable valuation range of over HKD 25 billion [21]. Core Insights - The company has transitioned from traditional generic drugs to a dual-driven strategy focusing on "aesthetic medicine and innovative drugs," leading to a significant revenue increase in the aesthetic segment [21]. - The aesthetic medicine segment saw a revenue increase of 81% year-on-year in the first half of 2025, contributing significantly to the company's overall revenue growth [4][11]. - The innovative drug segment is expected to enter a revenue realization phase with the commercialization of new drugs, enhancing the company's financial outlook [12][16]. Summary by Sections Aesthetic Medicine - In H1 2025, aesthetic medicine revenue increased by 81% to HKD 5.9 billion, with a gross margin improvement of 8 percentage points to 73% [4][11]. - The core product, Letybo (botulinum toxin), has a market penetration of less than 2% in China, indicating substantial growth potential compared to higher penetration rates in the US and South Korea [5]. - The company has three major products approved in 2025, including facial fillers and water light needles, which are expected to drive significant sales growth [9][10]. Innovative Drugs - The innovative drug segment reported a 30% revenue increase to HKD 0.17 billion in H1 2025, with a focus on gastrointestinal and oncology treatments [12]. - The company has successfully commercialized its first innovative PPI drug, which is expected to maintain its price in the national basic medical insurance directory [12][14]. - The company holds a 49.13% stake in Xuan Zhu Bio, which has a market capitalization of HKD 34.5 billion, further enhancing its financial position [12]. Biopharmaceuticals - The biopharmaceutical segment, focusing on diabetes, has a comprehensive pipeline with over 20 products, and revenue is expected to see explosive growth in the next 2-3 years [17][18]. - The company reported a 40-fold increase in revenue to HKD 0.39 billion in H1 2025, with a focus on insulin and innovative diabetes treatments [17][18]. Generic Drugs - Generic drug revenue decreased by 16% to HKD 5.0 billion in H1 2025, accounting for 44% of total revenue, but the impact is expected to lessen as aesthetic and innovative drug segments grow [19]. - Key products include Clinao (a unique injection) and a mucosal solution for children, which are positioned to capture niche markets [19]. Profit Forecast - The company is expected to turn profitable in 2025, with significant revenue growth driven by aesthetic and innovative drugs, alongside reduced R&D expenses [20]. - The company has maintained a high dividend payout ratio of 89% in H1 2025, reflecting strong cash flow management [20].

Group 1: New Oriental (EDU) - New Oriental's FY26Q2 net revenue increased by 14.7% year-on-year to $1.191 billion, slightly exceeding the previous guidance of $1.132 to $1.163 billion[9] - Operating profit reached $66.3 million, up 244.4% year-on-year, while Non-GAAP operating profit rose by 206.9% to $89.13 million[9] - The company adjusted its FY26 revenue guidance to between $5.292 billion and $5.49 billion, reflecting a year-on-year growth of 8% to 12%[12] Group 2: Financial Metrics - The target price for New Oriental is set at $78.00, representing a potential upside of 24.3% from the current price of $62.8[6] - The company's EPS for FY26 is projected to be $0.31, an increase of 3% from the previous estimate of $0.30[2] - The net profit margin improved by 0.7 percentage points to 3.8%, while Non-GAAP net profit margin increased by 1.9 percentage points to 6.1%[10] Group 3: Business Performance - New business revenue grew by 21.6% year-on-year, with non-academic tutoring registrations reaching 1.058 million, a 6.4% increase[11] - The number of active paid users for the smart learning system and devices reached 352,000, up 34.8% year-on-year[11] - The company operates 1,379 learning centers and schools, a significant increase from 1,189 in FY25Q2[11] Group 4: Market Outlook - The company expects FY26Q3 net revenue to be between $1.313 billion and $1.349 billion, indicating a year-on-year growth of 11% to 14%[12] - The overall positive performance is attributed to the recovery of new business growth and effective cost management, leading to improved profit margins[10]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the strong performance of the medical beauty and cosmetics sectors, with significant growth potential driven by consumer demand for emotional value and safety in products [8][50] - Key companies in the medical beauty sector include Meili Tianyuan Medical Health, which is expanding through acquisitions and strong operational strategies, and in the cosmetics sector, brands like HBN and Banmu Huatian are leading with innovative product offerings and market strategies [8][24][34] Summary by Sections Market Review - The beauty and personal care index rose by 0.44% in January, ranking 24th among all sectors, underperforming the overall market [14][15] - Notable stock performances in January included SiHuan Pharmaceutical (+28.5%) and Yonghe Medical (+22.7%) in the medical beauty sector, while Yiwan Yichuang (+50.8%) and Ruoyu Chen (+8.1%) led in cosmetics [5][15] Medical Beauty - The approval of a new composite solution by Juzhi Biotechnology marks a significant advancement in the field, showcasing the company's R&D capabilities [6][19] - Meili Tianyuan announced a positive earnings forecast, projecting revenues of at least 3 billion yuan for 2025, reflecting a growth of over 16% year-on-year [22] Cosmetics - Banmu Huatian's parent company has filed for an IPO, aiming to leverage its strong market position in body care products [24] - HBN, a leading domestic skincare brand, has also submitted its IPO application, highlighting its innovative product lines and strong sales performance [34] Investment Recommendations - The report recommends focusing on high-quality companies in the medical beauty and cosmetics sectors that cater to emotional consumption trends, with specific mentions of Meili Tianyuan, Aimeike, and Ruoyu Chen among others [8][49] - In cosmetics, brands like Maogeping and Porlaia are highlighted for their strong market positions and innovative strategies [50][52]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index (HSSCPB) decreased by 1.40% as of February 5, 2026, with mixed performance among constituent stocks [1] - Notable gainers included Nocera Healthcare up 3.87%, Four Seasons Pharmaceutical up 3.14%, and Heng Rui Medicine up 2.77%, while MIRXES-B led the decline down 9.12% [1] - The Hong Kong Innovative Drug ETF (520690) fell by 1.20%, with a latest price of 0.82 yuan, but showed a 2.97% increase over the past month as of February 4, 2026 [1] Group 2 - As of January 31, 2026, 283 pharmaceutical stocks disclosed their 2025 earnings forecasts, with 160 stocks expected to see year-on-year profit growth, highlighting a positive trend in the innovative drug sector [2] - Sino Medical emerged as the "profit growth king" in A-shares with a forecasted increase of over 32 times, while WuXi AppTec is expected to achieve a record net profit of 19.151 billion yuan [2] - The demand for weight loss drugs remains strong, with Eli Lilly reporting a 43% year-on-year revenue increase to $19.29 billion in Q4, exceeding market expectations [2] Group 3 - Donghai Securities indicated that the innovative drug sector is entering a phase of accelerated profit realization, driven by rapid commercialization of products and business development collaborations [3] - The performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core products supported by medical insurance driving growth [3] - The Hong Kong Innovative Drug ETF has seen continuous net inflows, totaling 16.3621 million yuan over three days, with a maximum single-day inflow of 8.9766 million yuan [3]

截至2026年2月5日 09:41，中证港股通医药卫生综合指数(930965)上涨0.32%，成分股银诺医药-B上涨 10.07%，药明康德上涨2.73%，海吉亚医疗上涨2.65%，再鼎医药上涨2.13%，四环医药上涨1.89%。港 股医药ETF(159718)下跌0.22%，最新报价0.92元。 消息面上，政策持续支持医药产业，国家药监局称，"十五五"期间将大力支持生物制造产业创新发展。 港股医药ETF紧密跟踪中证港股通医药卫生综合指数，中证港股通医药卫生综合指数从港股通范围内选 取50只流动性较好、市值较大的医疗卫生行业上市公司证券作为指数样本，以反映港股通范围内医药卫 生上市公司证券的整体表现。 数据显示，截至2026年1月30日，中证港股通医药卫生综合指数(930965)前十大权重股分别为药明生 物、百济神州、信达生物、康方生物、京东健康、石药集团、中国生物制药、翰森制药、药明康德、三 生制药，前十大权重股合计占比64.57%。 港股医药ETF(159718)，场外联接(平安中证港股医药ETF联接A：019598；平安中证港股医药ETF联接 C：019599；平安中证港股医药ETF联接E：024544 ...

Core Viewpoint - The era of upstream medical beauty supply chain manufacturers relying solely on price control to maintain high profits may be coming to an end, indicating a significant shift in the industry's development logic [2][4]. Group 1: Industry Dynamics - New Oxygen has reached cooperation agreements with 14 upstream manufacturers, including major players like Allergan and Huaxi Biological, marking a pause in the pricing power battle that dominated the previous year [3]. - The medical beauty industry is experiencing a restructuring of power dynamics between upstream and downstream players, suggesting a transformation in the overall industry landscape [4]. Group 2: Pricing Strategies - New Oxygen's founder, Jin Xing, aims to lower the prices of medical beauty projects, citing high operational costs and supplier pricing as key factors for the inflated prices in China compared to countries like South Korea [6]. - The introduction of the "Miracle Tongyan 1.0" project by New Oxygen, priced at 4,999 yuan per unit, significantly undercuts the traditional market price of over 10,000 yuan, leading to backlash from suppliers [6][7]. - The pricing strategy continued to evolve with the launch of "Miracle Tongyan 3.0," which further reduced the price to 2,999 yuan, setting a new low in the industry [7]. Group 3: Supplier Relationships - Despite previous conflicts, some suppliers have reconciled with New Oxygen, indicating a shift in relationships as the market dynamics change [9]. - New Oxygen's purchasing power has increased, allowing it to negotiate better prices with suppliers, as it has established a significant presence with 50 stores across 16 cities by the end of 2025 [11]. Group 4: Market Supply and Demand - The balance of pricing power is shifting towards buyers, with an increase in the number of suppliers and products available, leading to a more competitive market environment [11][14]. - The regulatory environment is improving, with a significant increase in the number of medical beauty device registrations, which is expected to further enhance supply [13]. Group 5: Future Outlook - The medical beauty industry is transitioning from a phase of rapid, unregulated growth to a more structured and value-focused era, emphasizing the importance of quality over price competition [14][16]. - New Oxygen faces challenges in maintaining its scale while achieving profitability and balancing relationships with suppliers, which will be crucial for its successful transformation [15].

Core Viewpoint - The era where upstream medical beauty supply chain manufacturers rely solely on price control to maintain high profits may be coming to an end, as evidenced by recent collaborations between New Oxygen and 14 upstream manufacturers, including major players like Sota, Allergan, Aimeike, Huaxi Biology, Jinbo Biology, and Sihuan Pharmaceutical [1] Group 1 - New Oxygen has reached agreements with 14 upstream manufacturers, indicating a shift in the dynamics of the medical beauty industry [1] - Previous conflicts over pricing between New Oxygen and several suppliers, which even led to supply disruptions, appear to have been temporarily resolved with these new partnerships [1] - Industry insiders believe that this collaboration reflects a restructuring of power between upstream and downstream players in the medical beauty sector, signaling a significant change in the industry's development logic [1]